Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 251 Ballardvale St WILMINGTON MA 01887 |
Tel: | N/A |
Website: | https://www.criver.com |
IR: | See website |
Key People | ||
James C. Foster Chairman of the Board, President, Chief Executive Officer | Flavia H. Pease Chief Financial Officer, Corporate Executive Vice President | Birgit Girshick Chief Operating Officer, Corporate Executive Vice President |
Victoria L. Creamer Corporate Executive Vice President and Chief People Officer | William D. Barbo Executive Vice President, Strategic Advisor | Joseph W. LaPlume Corporate Executive Vice President - Corporate Development and Strategy |
Shannon M. Parisotto Corporate Executive Vice President - Discovery and Safety Assessment Management | Kristen Eisenhauer Senior Vice President, Chief Commercial Officer |
Business Overview |
Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. The Company's Research Models and Services segment is comprised of three businesses that provide foundational tools that enables its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions. |
Financial Overview |
For the fiscal year ended 30 December 2023, Charles River Lbrtrs ntrntl Inc revenues increased 4% to $4.13B. Net income decreased 2% to $474.6M. Revenues reflect Discovery And Safety Assessment segment increase of 7% to $2.62B, Research Models segment increase of 7% to $792.3M, Canada segment increase of 22% to $487.3M, Europe segment increase of 4% to $1.08B, Asia Pacific (Region) segment increase of 4% to $200.8M. |
Employees: | 20,000 as of Dec 30, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $16,289M as of Dec 30, 2023 |
Annual revenue (TTM): | $4,129M as of Dec 30, 2023 |
EBITDA (TTM): | $967.26M as of Dec 30, 2023 |
Net annual income (TTM): | $474.62M as of Dec 30, 2023 |
Free cash flow (TTM): | $365.37M as of Dec 30, 2023 |
Net Debt Last Fiscal Year: | $2,376M as of Dec 30, 2023 |
Shares outstanding: | 51,349,770 as of Jan 27, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |